Andrew S Kennedy Selected Research

Neoplasm Metastasis (Metastasis)

10/2022	Survival and Toxicities after 90Y Transarterial Radioembolization of Metastatic Colorectal Cancer in the RESIN Registry.
5/2021	ACR-ABS-ACNM-ASTRO-SIR-SNMMI practice parameter for selective internal radiation therapy or radioembolization for treatment of liver malignancies.
6/2017	Locoregional therapy for liver metastases in colorectal cancer.
1/2017	Hepatopulmonary Shunting: A Prognostic Indicator of Survival in Patients with Metastatic Colorectal Adenocarcinoma Treated with 90Y Radioembolization.
2/2016	Hepatic-directed Therapies in Patients with Neuroendocrine Tumors.
12/2015	Hepatic imaging response to radioembolization with yttrium-90-labeled resin microspheres for tumor progression during systemic chemotherapy in patients with colorectal liver metastases.
4/2015	Multicenter evaluation of the safety and efficacy of radioembolization in patients with unresectable colorectal liver metastases selected as candidates for (90)Y resin microspheres.
1/2012	Patient selection and activity planning guide for selective internal radiotherapy with yttrium-90 resin microspheres.
6/2008	Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-microspheres: early results in 148 patients.
11/2007	Use of yttrium-90 microspheres in the treatment of unresectable hepatic metastases from breast cancer.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Andrew S Kennedy Research Topics

Disease

27	Neoplasms (Cancer) 03/2024 - 02/2003
12	Neoplasm Metastasis (Metastasis) 10/2022 - 01/2006
8	Hepatocellular Carcinoma (Hepatoma) 12/2023 - 09/2004
8	Colorectal Neoplasms (Colorectal Cancer) 10/2022 - 03/2010
7	Liver Neoplasms (Liver Cancer) 04/2023 - 10/2005
2	Fibrosis (Cirrhosis) 01/2023 - 01/2014
2	Adenocarcinoma 01/2017 - 01/2006
2	Neuroendocrine Tumors (Neuroendocrine Tumor) 02/2016 - 06/2008
1	Cholangiocarcinoma 01/2023
1	Ascites 04/2015
1	Necrosis 02/2011
1	Thrombosis (Thrombus) 09/2010
1	Melanoma (Melanoma, Malignant) 07/2009
1	Radiation Pneumonitis 10/2008
1	Breast Neoplasms (Breast Cancer) 11/2007
1	Liver Failure 03/2007
1	Drug-Related Side Effects and Adverse Reactions 01/2006
1	Fatigue 01/2006
1	Nausea 01/2006
1	Carcinoma (Carcinomatosis) 01/2006
1	Pancreatic Neoplasms (Pancreatic Cancer) 01/2006
1	Anorexia 01/2006
1	Colonic Neoplasms (Colon Cancer) 12/2004
1	Hepatitis 12/2004

Drug/Important Bio-Agent (IBA)

16	Yttrium-90IBA 12/2023 - 02/2003
4	SirtuinsIBA 05/2021 - 01/2006
2	YttriumIBA 10/2022 - 01/2017
2	Bevacizumab (Avastin)FDA Link 01/2017 - 01/2014
1	LipidsIBA 03/2024
1	Fatty Acids (Saturated Fatty Acids)IBA 03/2024
1	Hemoglobins (Hemoglobin)IBA 02/2017
1	Carcinoembryonic AntigenIBA 01/2017
1	Indicators and Reagents (Reagents)IBA 01/2017
1	AlbuminsIBA 04/2015
1	Alkaline PhosphataseIBA 04/2015
1	Aspartate Aminotransferases (Aspartate Transaminase)IBA 04/2015
1	Sorafenib (BAY 43-9006)FDA Link 01/2014
1	Biomarkers (Surrogate Marker)IBA 02/2011
1	Tumor Biomarkers (Tumor Markers)IBA 03/2007
1	Irinotecan (Camptosar)FDA LinkGeneric 06/2006
1	Oxaliplatin (Eloxatin)FDA LinkGeneric 06/2006
1	Docetaxel (Taxotere)FDA Link 01/2006
1	Cytotoxins (Cytolysins)IBA 10/2005

Therapy/Procedure

25	Microspheres (Microsphere) 01/2023 - 02/2003
15	Therapeutics 03/2024 - 02/2003
9	Drug Therapy (Chemotherapy) 01/2023 - 01/2006
7	Radiotherapy 05/2021 - 01/2006
4	Brachytherapy 05/2021 - 06/2006
2	Salvage Therapy 03/2010 - 06/2006
1	Surgical Instruments (Clip) 09/2010
1	Radiofrequency Ablation 06/2008
1	Aftercare (After-Treatment) 06/2008
1	Biological Therapy 01/2006
1	Adjuvant Chemotherapy 10/2005